Long-term Survival Outcomes Following Internal Mammary Node Irradiation in Stage II-III Breast Cancer: Results of a Large Retrospective Study With 12-Year Follow-up
Long-term Survival Outcomes Following Internal Mammary Node Irradiation in Stage II-III Breast Cancer: Results of a Large Retrospective Study With 12-Year Follow-up
复制标题
DOI：
10.1016/j.ijrobp.2013.02.037
复制
发表时间：
2013-08-01
影响因子：
7
通讯作者：
Huh, Seung Jae
中科院分区：
文献类型：
--
作者：
Chang, Jee Suk;Park, Won;Huh, Seung Jae
目的：研究内乳淋巴结照射（IMNI）对乳腺癌改良根治术和术后放疗患者的无病生存期（DFS）和总生存期（OS）的影响。方法和材料：在1994年至2002年期间，396名II-III期乳腺癌患者接受了乳房切除术后放射治疗（n=197）或不接受（n=199）IMNI。排除接受新辅助化疗的患者。IMNI由主治医生根据临床判断进行给药。中位RT剂量为50.4戈伊（范围45.0-59.4戈伊），分28次，96%的患者包括锁骨上窝。结果：随访124-202个月，中位随访时间149个月。IMNI患者的淋巴结分期和非高级别肿瘤较无IMNI者多（P
Purpose: To examine the effect of internal mammary node irradiation (IMNI) on disease-free survival (DFS) and overall survival (OS) in breast cancer patients treated with modified radical mastectomy and postoperative radiation therapy.Methods and Materials: Between 1994 and 2002, 396 patients with stage II-III breast cancer were treated with postmastectomy radiation therapy with (n=197) or without (n=199) IMNI. Patients who received neoadjuvant chemotherapy were excluded. IMNI was administered at the clinical discretion of the treating physician. Median RT dose was 50.4 Gy (range, 45.0-59.4 Gy) in 28 fractions, with inclusion of the supraclavicular fossa in 96% of patients. Adjuvant chemotherapy was administered to 99.7% of the patients and endocrine therapy to 53%.Results: The median follow-up was 149 months (range, 124-202). IMNI patients had more advanced nodal stage and non-high grade tumors than those without IMNI (P